Bicycle Therapeutics
在场
Bicycle Therapeutics 是一家在股票代码 BCYC (US) 下上市的公司。
高管
查看带有其 27 名主要高管的组织结构图
Bicycle Therapeutics 搜索最多的简介
- Kevin Lee, Chief Executive Officer and Director
- Jose-Carlos Gutierrez-Ramos, Director
- Greg Winter, Director
高管在Bicycle Therapeutics变化
- Mike Hannay 曾任 Senior Vice President and and Head of Chemistry, Manufacturing and Controls, 现升职为 Chief Product and Supply Chain Officer (新闻发布的2024五月3号).
- Veronica Jordan, Director, 已经离开公司 (新闻发布的2024四月19号).
- Felix Baker已作为Director加入公司 (新闻发布的2024四月19号).
创建提醒
跟踪 Bicycle Therapeutics 的高管变动
生物技术
Bicycle Therapeutics 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
- Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
- TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).
生物技术 行业的其他推荐联系人
消息
Bicycle Therapeutics 的最新新闻稿
- Press Releases | Bicycle Therapeutics
- Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update | Bicycle Therapeutics
- Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry | Bicycle Therapeutics
- Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration | Bicycle Therapeutics
- Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression | Bicycle Therapeutics
- Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference | Bicycle Therapeutics
- Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting | Bicycle Therapeutics
- Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update | Bicycle Therapeutics
- Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting | Bicycle Therapeutics
- Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting | Bicycle Therapeutics
- View more press releases Close
通过电子邮件
